AGN Allergan plc

182.2
+1.12  (+1%)
Previous Close 181.08
Open 181.9
Price To Book 1.03
Market Cap 59,944,167,133
Shares 329,002,015
Volume 4,269,304
Short Ratio 3.88
Av. Daily Volume 4,034,309
Stock charts supplied by TradingView

NewsSee all news

  1. Block Trade: AGN 1.1M @ $178.15

  2. ZYNGA INC (FormDEF 14A) (0001564590-20-015517)

  3. China Gives Greenlight to Allergan's XEN® Registration for the Surgical Management of Refractory Glaucoma

    -- XEN® Becomes the First Medical Product Approved by Using Real World Evidence in China -- DUBLIN, April 2, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced China's National Medical Products

  4. Allergan Earns ENERGY STAR® Partner of the Year - Sustained Excellence Award for the Seventh Consecutive Year

    DUBLIN, March 31, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced it has received the ENERGY STAR® Partner of the Year Sustained Excellence Award for 2020, marking the seventh consecutive year it has earned

  5. The Allergan Foundation Donates $2.0 Million to Community Organizations on Front-Line of COVID-19 Response

    DUBLIN, March 30, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that The Allergan Foundation has awarded approximately $13 million in charitable grants in 2020 as part of its commitment to providing a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval (third indication) announced October 3, 2017.
Botox
Forehead lines
Phase 2 trial ongoing.
RTGel in combination with BOTOX
Overactive Bladder (OAB)
Approval announced March 20, 2017.
JUVÉDERM VOLLURE
Correction of moderate to severe facial wrinkles and folds
Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Botox
Depression
Phase 2b trial ongoing.
RORγt agonist
Psoriasis
Approval announced November 13, 2017.
Cariprazine
Maintenance Treatment of Schizophrenia
BLA filing announced December 19, 2019.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
Phase 3 data due in 2020.
ATOGEPANT
Chronic migraine
Phase 3 trials did not meet primary endpoints - March 6, 2019.
RAPASTINEL
Major depressive disorder (MDD)
Phase 3 top-line data due 2020.
RELAMORELIN
Diabetic Gastroparesis
CRL issued August 21, 2018.
ESMYA (ulipristal acetate)
Uterine Fibroids
Phase 3 trial to be initiated 2019.
ABICIPAR
Diabetic macular edema (DME)
Phase 3 data due 2021.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
BLA acceptance of filing announced September 9, 2019. Estimated PDUFA date July 9, 2020.
ABICIPAR
Age-related macular degeneration (AMD)
sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI)
Approved January 19, 2017.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
FDA Approval announced May 28, 2019.
Cariprazine
Bipolar I Depression
FDA Approval announced December 23, 2019.
Ubrogepant
Migraine
Phase 3 trial to be initiated 2H 2018.
Brimo DDS
Geographic atrophy
FDA approval announced March 5, 2020.
Bimatoprost
Open-angle glaucoma or ocular hypertension
FDA Approval announced March 18, 2019.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI) - pediatric
FDA Approval announced October 24, 2019.
Botox
Lower limb spasticity
FDA Approval announced June 21, 2019.
Botox
Upper limb spasticity
Phase 3 top-line data due 2020.
Presbysol
Presbyopia
FDA Approval announced September 3, 2019.
Juvéderm VOLUMA
Mid-Face Injection Via Cannula

Latest News

  1. Block Trade: AGN 1.1M @ $178.15

  2. ZYNGA INC (FormDEF 14A) (0001564590-20-015517)

  3. China Gives Greenlight to Allergan's XEN® Registration for the Surgical Management of Refractory Glaucoma

    -- XEN® Becomes the First Medical Product Approved by Using Real World Evidence in China -- DUBLIN, April 2, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced China's National Medical Products

  4. Allergan Earns ENERGY STAR® Partner of the Year - Sustained Excellence Award for the Seventh Consecutive Year

    DUBLIN, March 31, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced it has received the ENERGY STAR® Partner of the Year Sustained Excellence Award for 2020, marking the seventh consecutive year it has earned

  5. The Allergan Foundation Donates $2.0 Million to Community Organizations on Front-Line of COVID-19 Response

    DUBLIN, March 30, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that The Allergan Foundation has awarded approximately $13 million in charitable grants in 2020 as part of its commitment to providing a

  6. Allergan Declares Second Quarter 2020 Cash Dividend of $0.74 Per Ordinary Share

    DUBLIN, March 18, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the second quarter of 2020. The dividend will be

  7. AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction

    NORTH CHICAGO, Ill. and DUBLIN, March 17, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE:AGN), a leading global pharmaceutical company, today announced

  8. Announcement under the Irish Takeover Rules: Relevant Securities in Issue - March 10, 2020

    DUBLIN, March 10, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN

  9. Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients

    DUBLIN, March 5, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has

  10. Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

    AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients Additional patient enrollment to the BRILLIANCE Clinical Trial is ongoing DUBLIN, Ireland and CAMBRIDGE, Mass., March 04, 2020

  11. Announcement under the Irish Takeover Rules: Relevant Securities in Issue - March 3, 2020

    DUBLIN, March 3, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN

  12. AbbVie and Allergan Receive Final European Approval to Close Pending Transaction

    NORTH CHICAGO, Ill. and DUBLIN, March 3, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE:AGN), a leading global pharmaceutical company, today announced

  13. Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meeting

    DUBLIN, Feb. 25, 2020 /PRNewswire/ -- Allergan plc, (NYSE:AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology, will present new data from investigational Bimatoprost

  14. Announcement under the Irish Takeover Rules: Relevant Securities in Issue - February 14, 2020

    DUBLIN, Feb. 14, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  15. Announcement under Rule 8.1(a) of the Irish Takeover Rules: Dealings by Offerors, Offerees or Parties Acting in Concert With Them for Themselves or for Discretionary Clients

    DUBLIN, Feb. 14, 2020 /PRNewswire/ -- Ap9 APPENDIX 3

  16. BOTOX® Cosmetic (onabotulinumtoxinA) Launches Be The Difference Philanthropic Program

    DUBLIN, Feb. 3, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) announced today its Be The Difference philanthropic program supporting children and their families who may benefit from treatment with BOTOX®

  17. Allergan to Report Fourth Quarter and Full Year 2019 Financial Results

    DUBLIN, Jan. 31, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced it will release fourth quarter and full year 2019 financial results on Monday, February 10, 2020, prior to the open of U.S. financial

  18. Announcement under the Irish Takeover Rules: Relevant Securities in Issue - January 30, 2020

    DUBLIN, Jan. 30, 2020 /PRNewswire/ --  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  19. AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

    NORTH CHICAGO, Ill. and DUBLIN, Jan. 27, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE:AGN), a leading global pharmaceutical company, today announced that

  20. Allergan Declares First Quarter 2020 Cash Dividend of $0.74 Per Ordinary Share

    DUBLIN, Jan. 24, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the first quarter of 2020. The dividend will be paid

  21. Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS® (linaclotide) Patent Litigation

    – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc.

  22. SkinMedica® Launches New Instant Bright Eye Cream For Immediate, Visible Results

    DUBLIN, Jan. 17, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN) announced today the launch of the SkinMedica® Instant Bright Eye Cream, a refreshing eye treatment that hydrates, brightens and helps visibly firm the

  23. Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma's Impact on Daily Living

    DUBLIN, Jan. 16, 2020 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, announced today a partnership with Von Miller, Super Bowl MVP,

  24. Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Allergan plc (NYSE:AGN) announced today that the companies have reached an agreement with Sandoz Inc. (Sandoz) resolving patent litigation brought in response to Sandoz's

  25. Allergan Receives U.S. FDA Approval for UBRELVY™ for the Acute Treatment of Migraine with or without Aura in Adults

    DUBLIN, Dec. 23, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for UBRELVY™ (ubrogepant) for the acute treatment

  26. Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration

    THOUSAND OAKS, Calif., Dec. 19, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)

  27. Allergan Foundation Giving Reaches $95 Million Since Inception

    IRVINE, Calif., Dec. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, today announced that The Allergan Foundation has awarded a total of $10 million in charitable grants in

  28. Silicone Market Seeing 22.5% CAGR Growth to Garner $91.4 Billion by 2026

    PUNE, India, Dec. 18, 2019 /PRNewswire/ -- A new report added by Big Market Research states that the global silicone market is expected to reach $91.4 billion by 2026 and grow at a healthy growth rate of 22.5% from 2019

  29. BOTOX® (onabotulinumtoxinA) Celebrates 30 Years of Endless Innovation

    DUBLIN, Dec. 16, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) is commemorating today the beginning of the 30th anniversary celebration for BOTOX® this year with the ringing of the New York Stock Exchange opening bell.

  30. Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine

    DUBLIN, Dec. 4, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the efficacy, safety and tolerability of

  31. Announcement under the Irish Takeover Rules: Relevant Securities in Issue - November 29, 2019

    DUBLIN, Nov. 29, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  32. Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association

    DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the efficacy, safety and tolerability of

  33. Allergan® Announces First Annual National BOTOX® Cosmetic (onabotulinumtoxinA) Day

    DUBLIN, Nov. 18, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN), the maker of BOTOX® Cosmetic, has announced the first-ever National BOTOX® Cosmetic Day kicking off on November 20. The celebration recognizes the impact

  34. Exicure and Allergan Enter Into Collaboration, Option and License Agreement to Discover and Develop SNA-based Treatments for Hair Loss Disorders

    - Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones - Exicure to Host Conference Call Today at 8:30am ET/7:30am CT Exicure, Inc., (NASDAQ:XCUR) a pioneer in gene regulatory

  35. Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For Antibiotic-Resistant Gram-Negative Infections

    DUBLIN, Nov. 11, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation and Fast Track Designation for

  36. FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs

    SAN FRANCISCO and DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, and Allergan plc (NYSE:AGN), a leading global

  37. Allergan Declares Fourth Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share

    DUBLIN, Oct. 25, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the fourth quarter of 2019. The dividend will be paid

  38. FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy

    DUBLIN, Oct. 24, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX® for

  39. Allergan Presents Data From Eleven Abstracts At The 2019 American Society for Dermatologic Surgery (ASDS) in Chicago

    DUBLIN, Oct. 23, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that its data will be featured during the 2019 American Society for Dermatologic Surgery Annual Meeting in Chicago, IL October 24-27 2019.

  40. Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

    DUBLIN, Oct. 11, 2019 /PRNewswire/ -- Allergan plc, (NYSE:AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: MOLN), a clinical-stage

  41. On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living

    DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced a national education campaign called My Glaucoma.

  42. On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living

    DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced a national education campaign called My Glaucoma.

  43. Allergan Expands REFRESH® Portfolio With New REFRESH® RELIEVA™ Lubricant Eye Drop Product Line

    DUBLIN, Oct. 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in eye care, today announced the launch of three new over-the-counter (OTC)

  44. Late-Stage Data from Abicipar in Age-Related Macular Degeneration to be Showcased at American Academy of Ophthalmology (AAO) Annual Meeting

    ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 4, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced

  45. Allergan to Showcase Late-Stage Data in Age-Related Macular Degeneration and Glaucoma at American Academy of Ophthalmology Annual Meeting

    DUBLIN, Oct. 3, 2019 /PRNewswire/ -- Allergan plc, (NYSE:AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology, will present new data from investigational Abicipar and

  46. Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction

    DUBLIN, Sept. 27, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS

  47. AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction

    NORTH CHICAGO, Ill., Sept. 27, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that, as expected, AbbVie and Allergan (NYSE:AGN) have each received a Request

  48. Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

    Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

  49. SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies Is Fair to Shareholders – AGN, ORIT, MCRN, GHDX

    NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Allergan plc (NYSE:AGN)The investigation concerns whether Allergan

  50. Announcement under the Irish Takeover Rules: Relevant Securities in Issue - September 17, 2019

    DUBLIN, Sept. 17, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  51. Allergan Announces Commencement of Mailing of Proxy Statement

    DUBLIN, Sept. 17, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  52. Allergan Shareholder Meetings Scheduled for October 14, 2019

    DUBLIN, Sept. 10, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE

  53. Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration

    DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology

  54. Allergan Receives FDA Approval of Juvéderm VOLUMA® XC For Mid-Face Injection Via Cannula

    DUBLIN, Sept. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) announced today it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA® XC, a hyaluronic acid gel dermal filler, with a

  55. Allergan Announces Settlement with Two Ohio Plaintiffs in Federal Opioid Litigation

    DUBLIN, Aug. 30, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that the Company and its U.S. subsidiaries have reached a settlement with plaintiffs scheduled for trial in October 2019 in the federal opioid

  56. Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)

    THOUSAND OAKS, Calif., Aug. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP